Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares slip on inflation worries, Germany leads fall

Wed, 17th Aug 2022 17:22

Aug 17 (Reuters) - European shares slid on Wednesday and bond yields rallied after a sharp rise in UK inflation brought the spotlight back to more monetary tightening amid data which showed euro zone economic growth was slightly less robust in the second quarter.

The pan-European STOXX 600 shed 0.9%, clocking its biggest one-day percentage fall in more than a month. The index also snapped a five-day winning streak.

Data showed British consumer price inflation rose to 10.1% in July, its highest since February 1982. Britain's FTSE 100 fell 0.3%.

"The market is seeing the UK experience as a harbinger of what is to come in the EU," said Stuart Cole, chief macro economist at Equiti Capital.

Euro zone government bond yields jumped after the inflation reading, while investors also turned their focus to data which showed economic growth in the bloc was less-than-expected in the second quarter but still strong, and employment rose again.

European bourses have bounced off June lows, but have been struggling to make headway in August on growing concerns of a recession, high inflation and low water levels in the Rhine river.

The river is Germany's main commercial artery, which is now experiencing a block, with 20 ships stuck in traffic after a vessel's engine failure closed part of the waterway.

German stocks fell 2.0%.

"Rhine troubles add to pressure on the German industry," said Andrew Kenningham, chief Europe economist at Capital economics.

He noted that even if it is a smaller problem for Germany compared to the gas crisis or a recent shortage of semiconductors, if it persists until December it could weigh on economic growth and add to inflation.

Money markets in the euro zone, meanwhile, continue to fully price in a 50-basis point European Central Bank rate hike in September.

Among stocks, Uniper dropped 12.1% after the German utility reported a first-half net loss of 12.3 billion euros ($12.5 billion), mainly due to lower Russian gas supplies.

Sanofi fell 5.7% after the French healthcare company stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure.

Switzerland's biggest life insurer Swiss Life rose 0.3% after posting a 4% rise in its half-yearly net profit.

Danish brewer Carlsberg jumped 3.9% as it said it had not seen rising living costs impacting beer sales.

(Reporting by Anisha Sircar and Shreyashi Sanyal in Bengaluru; editing by Uttaresh.V and Emelia Sithole-Matarise)

More News
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
13 Feb 2023 17:19

European shares rise as defence stocks rally, focus on U.S. inflation data

STOXX 600 ends up 0.9%

*

Read more
3 Feb 2023 17:27

European shares log weekly gains, UK's blue-chip index hits record high

STOXX 600 up 0.3%, logs gains for second straight week

*

Read more
3 Feb 2023 11:49

Sanofi forecasts moderate profit growth on Dupixent demand

Sees "low single digit" percentage core EPS growth, FX adjusted

*

Read more
31 Jan 2023 12:26

Share buybacks in Europe as significant as in U.S.

STOXX 600 down around 1%

*

Read more
31 Jan 2023 11:30

Banks: six reasons to be overweight

STOXX 600 down 1%

*

Read more
31 Jan 2023 09:15

STOXX slides

STOXX 600 down 0.5%

*

Read more
31 Jan 2023 07:36

European shares seen lower

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

Read more
31 Jan 2023 06:56

Mind the gap

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MIND THE GAP (0656 GMT)

Read more
30 Jan 2023 20:27

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
30 Jan 2023 17:42

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
4 Jan 2023 10:51

Sanofi sees decision on Zantac dispute with Boehringer in Q1 at earliest

Arbitration decision initially expected by end of 2022

*

Read more
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.